LRRK2 and Parkinson disease: LRRK2 has been shown to bind to microtubules under overexpression conditions, an interaction that is enhanced by several of the most common PD-linked mutations (33, 43), and by treatment of cells with Type I kinase inhibitors that target LRRK2 (36).